FutureChem
FutureChem is a South Korea-based radiopharmaceutical company running 2 late-stage cancer trials of [F-18]Florastamin in prostate cancer.
Overview
FutureChem, based in Seoul, South Korea, is a radiopharmaceutical company. FUTURECHEM is a radiopharmaceutical drug-development company specialising in PET diagnostic imaging agents for neurological and oncological conditions. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing [F-18]Florastamin in prostate cancer. The largest, NCT05004285 (Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis), plans to enrol 398 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +2
- 24-month regulatory events +2
- registry trials +3
Florastamin is FutureChem's fluorine-18 PSMA PET tracer, and the first prostate cancer diagnostic developed in South Korea to be approved there — Korea's 43rd domestically developed new drug.
Similar pages
not linked directly; found by shared links- CompanyCellBion
Shares Korea Institute of Radiological and Medical Sciences, Nuclear Medicine and Molecular Imaging, Korean Society of Nuclear Medicine.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares Florastamin F-18, Fluorine-18, Prostate cancer.
- CompanyDuChemBio
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Fluorine-18, Prostate cancer.
- TrialAnti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Shares Fluorine-18, Prostate cancer.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares Fluorine-18, Prostate cancer.
- AgentCholine C-11
Shares Fluorine-18, Prostate cancer.
- TrialDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Shares Fluorine-18, Prostate cancer.